home · filing · 0001213900-23-004450
8-K
filed January 23, 2023, 6:59 PM ET
ticker RBOT
CIK 0001812173
leadership
confidence high
sentiment neutral
materiality 0.25
Vicarious Surgical appoints Victoria Carr-Brendel to board; Phil Liang resigns
Vicarious Surgical Inc.
Victoria Carr-Brendel, Ph.D., appointed to board effective Jan 23, 2023; deemed independent under NYSE rules.
Carr-Brendel is Group VP of Cochlear Implants at Sonova Group and President of Advanced Bionics.
She previously served as CEO of JenaValve and held roles at Boston Scientific (NYSE:BSX).
Philip Liang resigned from board effective Jan 23, 2023; not due to any disagreement with the company.
Standard nonemployee director compensation and indemnification agreement apply to Carr-Brendel.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2023-01-23
Filed January 23, 2023, 6:59 PM ET
Philip Liang, a member of the Board, notified the Company that he is resigning from the Board, effective as of January 23, 2023.
Effective 2023-01-23
Filed January 23, 2023, 6:59 PM ET
appointed Victoria Carr-Brendel, Ph.D. to the Board, effective as of January 23, 2023.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Philip Liang resigned as Director at Vicarious Surgical Inc..
Action resigned
Role Director
Exact text from the filing
Philip Liang, a member of the Board, notified the Company that he is resigning from the Board, effective as of January 23, 2023.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Victoria Carr-Brendel was appointed as Director at Vicarious Surgical Inc..
Action appointed
Role Director
Exact text from the filing
appointed Victoria Carr-Brendel, Ph.D. to the Board, effective as of January 23, 2023.
View on SEC.gov
Source: SEC EDGAR
accession 0001213900-23-004450
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.